Effect of Dietary Protein Restriction on Prognosis in Patients With Diabetic Nephropathy
Launched by STENO DIABETES CENTER COPENHAGEN · Jan 30, 2012
Trial Information
Current as of April 24, 2025
Completed
Keywords
ClinConnect Summary
The study was a prospective, randomized, unmasked, controlled trial carried out at the Steno Diabetes Center. With concealed randomization the patients were (in blocks of two according to the level of GFR) assigned to receive either a usual-protein diet or a low-protein diet.
After randomization an iso-caloric low-protein diet of 0.6 g/kg/day was prescribed to patients in the low-protein diet group. The usual-pro tein diet consisted of the patients' pre-study diet.
The planned duration of follow-up was four years, scheduled visits every three-months. All patients gave complete history of ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diabetes mellitus type 1
- • duration at least 10 years
- • onset before age of 35,
- • presence of diabetic retinopathy
- • albuminuria\>=300mg/24 h in at least 2/3 sterile urine samples
- • no clinical or laboratory evidence of other kidney or urinary tract disease
- • GFR above 20mL/min/1.73M2
- • pre-study decline in GFR\>= 2 mL/min/year
- Exclusion Criteria:
- • pregnancy
- • history of congestive heart failure or myocardial infarction or coronary bypass surgery within the last three months
Trial Officials
Henrik P Hansen, MD
Principal Investigator
Steno Diabetes Center Copenhagen
About Steno Diabetes Center Copenhagen
Steno Diabetes Center Copenhagen is a leading clinical research facility dedicated to advancing the understanding and treatment of diabetes and its complications. As a prominent sponsor of clinical trials, the center focuses on innovative research that bridges clinical practice and scientific inquiry, fostering collaborations with healthcare professionals, researchers, and patients. Committed to improving patient outcomes, Steno Diabetes Center Copenhagen emphasizes evidence-based approaches and cutting-edge methodologies to enhance diabetes management and care, ultimately contributing to the global fight against this chronic disease.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Gentofte, , Denmark
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials